|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD
65.27 Million
|
|
CAGR (2025-2030)
|
4.56%
|
|
Fastest Growing Segment
|
Ethylene Vinyl Alcohol Copolymer (EVOH)
|
|
Largest Market
|
Midwest
|
|
Market Size (2030)
|
USD 84.32 Million
|
Market Overview
United States Liquid Embolic Agent
Market was valued at USD 65.27 Million in 2024 and is expected to reach USD
84.32 Million by 2030 with a CAGR of 4.56%. Liquid embolic agents, which are
specialized substances used to block blood flow in targeted vessels, play a
crucial role in treating a variety of conditions such as arteriovenous
malformations, aneurysms, and hypervascular tumors. These agents have become
indispensable tools in interventional radiology, enabling clinicians to perform
precise and effective vascular occlusion.
Technological innovations have
significantly enhanced the market’s potential. Developments in embolic
materials, including cyanoacrylate-based adhesives and ethylene vinyl alcohol
copolymers, have improved the safety and control of embolization procedures. Despite
the optimistic outlook, the market faces challenges that could impact its
trajectory. The high cost associated with embolization procedures, including
the price of specialized materials and equipment, may limit widespread
adoption, particularly among cost-sensitive patient populations. Regulatory
requirements present another hurdle; stringent approval processes for new
embolic agents can delay market entry and inhibit innovation.
Key Market Drivers
Growth
in Healthcare Industry
In 2023, U.S. healthcare expenditure increased by 7.5
percent, totaling USD 4.9 trillion, which equates to USD 14,570 per capita.
Healthcare spending represented 17.6 percent of the country’s Gross Domestic
Product. The robust growth of the healthcare industry in the United States is a
significant driver fueling the expansion of the liquid embolic agent market.
Increasing prevalence of vascular diseases, such as aneurysms, arteriovenous
malformations (AVMs), and other cerebrovascular disorders, has intensified the
demand for minimally invasive treatment options, where liquid embolic agents
play a critical role.
Advancements in medical technology and a growing focus
on improving patient outcomes have led healthcare providers to adopt innovative
embolization techniques that rely on these agents to effectively occlude blood
vessels. The 2021 American Rescue Plan Act allocated USD 1 trillion to the
construction, renovation, and modernization of healthcare facilities.
Additionally, in the same year, the Build Back Better Act earmarked USD 10
billion for healthcare facility-related projects. The expanding healthcare
infrastructure, coupled with rising patient awareness and early diagnosis, has
contributed to a higher volume of interventional procedures that utilize liquid
embolic materials.
Surge
in Technological Advancements
The United States Liquid Embolic Agent market is
witnessing significant growth, largely fueled by a surge in technological
advancements that are enhancing the safety, efficacy, and versatility of
embolization procedures. For instance, Prostatic Artery Embolization (PAE)
has demonstrated effectiveness in treating urinary symptoms associated with
benign prostatic hyperplasia. Additionally, Cone Beam Computed Tomography
(CBCT) has been identified as a valuable tool in supporting the PAE procedure. These
innovations are driving wider adoption across a range of clinical applications,
including the treatment of vascular abnormalities, aneurysms, and tumors.
Recent developments in biomaterials and polymer
chemistry have led to the creation of next-generation liquid embolic agents
with improved biocompatibility, controlled polymerization rates, and enhanced
radiopacity. Such advancements enable precise delivery and better visualization
during minimally invasive procedures, reducing the risk of complications and
improving patient outcomes.
Download Free Sample Report
Key Market Challenges
High
Treatment and Product Costs
High treatment and product costs
represent a significant challenge for the United States Liquid Embolic Agent
Market, impacting both healthcare providers and patients. The specialized
nature of liquid embolic agents, combined with the complexity of associated
endovascular procedures, drives up the overall expense of treatment. These
costs include not only the price of the embolic materials themselves but also
the use of advanced delivery systems, imaging technologies, and the skilled
expertise required for successful intervention.
The premium pricing of liquid embolic
agents can limit their accessibility, especially among patients without
comprehensive insurance coverage or those in cost-sensitive healthcare
settings. Hospitals and surgical centers may face budgetary constraints when
procuring these products, which can influence treatment decisions and
potentially restrict the availability of cutting-edge embolization therapies.
Key Market Trends
Rising
Preference for Minimally Invasive Procedures
The rising preference for minimally
invasive procedures is a key trend driving the growth of the United States
liquid embolic agent market. In the United States, laparoscopic
cholecystectomy was the key procedure that drove the adoption of laparoscopy.
Its widespread acceptance as the standard of care has been largely due to
several advantages, including enhanced visualization, reduced risk of
infection, and the ability to perform the procedure on an outpatient basis. As
healthcare providers and patients increasingly seek treatment options that
offer reduced risk, shorter hospital stays, and faster recovery times, liquid
embolic agents have gained prominence as essential tools in interventional
radiology and endovascular therapies.
Minimally invasive techniques utilizing
liquid embolic agents enable precise occlusion of blood vessels to treat
conditions such as aneurysms, arteriovenous malformations (AVMs), and tumors
without the need for open surgery. This approach not only minimizes patient
trauma but also lowers complications and improves overall clinical outcomes,
making it highly attractive to clinicians and healthcare systems.
Segmental Insights
Product
Insights
Based on Product, Ethylene Vinyl Alcohol
Copolymer (EVOH) have emerged as the fastest growing segment in the United
States Liquid Embolic Agent Market in 2024. This is due to its superior
clinical performance and increasing preference among interventional
radiologists and neurosurgeons. EVOH-based embolic agents offer distinct
advantages in terms of precision, control, and safety during minimally invasive
vascular procedures. One of the key reasons for EVOH’s rapid growth is its
unique physical and chemical properties. EVOH provides excellent visibility
under fluoroscopy, enabling clinicians to monitor and control the embolization
process in real time.
Application
Insights
Based on Application, Arteriovenous
Malformations (AVM) have emerged as the fastest growing segment in the United
States Liquid Embolic Agent Market during the forecast period. This is due to
several key factors. AVMs, which are abnormal connections between arteries and
veins, require precise and effective treatment to prevent serious complications
such as hemorrhages and neurological damage. The rising prevalence of AVMs,
coupled with increasing awareness and improved diagnostic capabilities, has
driven greater demand for minimally invasive treatment options. Liquid embolic
agents offer significant advantages in AVM management, including targeted
occlusion, reduced procedure times, and improved patient outcomes, making them
the preferred choice among clinicians.
Download Free Sample Report
Regional Insights
Based on Region, Midwest have emerged as
the dominating region in the United States Liquid Embolic Agent Market in 2024.
This is due to several strategic and market-driven factors. Firstly, the region
benefits from a strong presence of leading medical device manufacturers and
research institutions specializing in vascular and neurovascular technologies,
which fosters innovation and accelerates product development. Additionally, the
Midwest's well-established healthcare infrastructure, including numerous
specialized hospitals and advanced treatment centers, supports high adoption
rates of liquid embolic agents for a variety of clinical applications.
Recent Development
- In July 2025, Medtronic announced the
enrollment of the first patient in the PELE clinical trial, which will assess
its Peripheral Onyx Liquid Embolic System (LES). Conducted under an
Investigational Device Exemption (IDE), the trial aims to evaluate the safety
and effectiveness of the Onyx LES for treating arterial hemorrhage in the
peripheral vasculature. According to the company, the prospective, multicenter,
non-randomized, single-arm study will include up to 119 patients across as many
as 25 sites in the United States. Primary safety and efficacy outcomes will be
assessed 30 days post-treatment.
- In March 2024, CERENOVUS Inc., a rising
leader in neurovascular care and a part of Johnson & Johnson MedTech,
announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set.
This latest addition to the CERENOVUS hemorrhagic stroke portfolio introduces a
comprehensive procedural set that includes two configuration options along with
the necessary accessories to prepare and deliver the n-BCA Liquid Embolic
System in a single sterilized package streamlining procedural setup. The
TRUFILL n-BCA system is designed for use under fluoroscopic guidance to reduce
or obstruct blood flow to cerebral arteriovenous malformations (AVMs) through
super-selective catheter delivery, particularly when pre-surgical
devascularization is required.
Key Market Players
- Medtronic
PLC
- Terumo
Medical Corporation
- Boston
Scientific Corporation
- Johnson
& Johnson Services, Inc.
- BlackSwan
Vascular, Inc.
|
By Product
|
By Application
|
By Region
|
- Ethylene Vinyl Alcohol Copolymer (EVOH)
- Cyanoacrylates
- Others
|
- Arteriovenous Malformations (AVM)
- Hypervascular Tumors
- Peripheral Vasculature Hemorrhage
- Others
|
- Northeast
- Midwest
- South
- West
|
Report Scope
In this report, the United States Liquid Embolic
Agent Market has been segmented into the following categories, in addition to
the industry trends which have also been detailed below:
- United States Liquid Embolic
Agent Market, By
Product:
o Ethylene Vinyl Alcohol Copolymer (EVOH)
o Cyanoacrylates
o Others
- United States Liquid Embolic
Agent Market, By
Application:
o Arteriovenous Malformations (AVM)
o Hypervascular Tumors
o Peripheral Vasculature Hemorrhage
o Others
- United States Liquid Embolic
Agent Market, By Region:
o Northeast
o Midwest
o South
o West
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the United States Liquid Embolic Agent Market.
Available Customizations:
United States Liquid Embolic Agent Market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
United States Liquid
Embolic Agent Market is an upcoming report to be released soon. If you wish an
early delivery of this report or want to confirm the date of release, please
contact us at [email protected]